Business Wire

Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes

Share

Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer Discovery, a journal of the American Association for Cancer Research, titled “Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing” from the laboratory of Prof. Berend Snijder. This post-hoc analysis builds on the transformative work of the EXALT-1 trial, published in Cancer Discovery, by using deep learning algorithms to classify complex cell morphologies in patient cancer tissue samples into disease “morphotypes.”

EXALT-1 was the first prospective trial to demonstrate significantly improved outcomes for late-stage haematological cancer patients using an AI-supported precision medicine platform to guide personalised treatment recommendations as compared to physician’s choice of treatment. In EXALT-1, 40% of patients experienced exceptional responses lasting at least three times longer than expected for their respective disease. The post-hoc analysis published today in Blood Cancer Discovery shows that combining the technology as used in EXALT-1 with new deep learning advancements that take advantage of cell-specific features in high-content images revealed a potential to further increase these patient outcomes.

“Following results of the EXALT-1 study, these findings continue to validate that our AI-guided precision medicine platform has the ability to identify highly actionable clinical treatment recommendations for blood cancers, deepening our insights and enhancing the clinical predictive power of the platform to help patients,” said Gregory Vladimer, Ph.D., VP Translational Research at Exscientia and co-inventor of the platform technology. “Cell morphology, or assessing the characteristics of cells, is fundamental to the diagnosis of cancer. Within this research, we were able to utilise deep learning within the platform to improve our ability to identify personalised cancer treatments, leading to improved clinical outcomes for patients. At Exscientia, we are excited to expand the platform’s applications in order to bring personalised medicine to broader populations.”

“We believe performing drug screens directly in tumour tissues of cancer patients is a great step forward in understanding tumour complexity compared to traditional cell model systems. The fact that we can now harness the power of deep learning to turn these terabytes of images into actionable insights is very exciting indeed,” added Prof. Berend Snijder, Principal Investigator at the Institute of Molecular Systems Biology of the ETH Zurich in Switzerland.

The impact of deep learning on the clinical predictive power of ex vivo drug screening was assessed in a post-hoc analysis of 66 patients over a period of three years in a combined data set of 1.3 billion patient cells across 136 ex vivo tested drugs across haematological diagnoses including acute myeloid leukaemia, T-cell lymphomas, diffuse large B-cell lymphomas, chronic lymphocytic leukaemia and multiple myeloma. Patients receiving treatments that were recommended by the platform’s immunofluorescence analysis or deep learning on cell morphologies showed an increased rate of achievement of exceptional clinical response, defined as a progression free survival period that lasted three times longer than expected for each patient’s respective disease. Post-hoc analyses confirmed that the clinical predictions became more accurate when also considering the drug toxicity on the healthy cells within the tested patient sample.

Exscientia’s precision medicine platform uses custom deep learning and computer vision techniques to extract meaningful single-cell data from high content images of individual patient tissue samples. This analysis generates clinically-relevant insights into which treatments will deliver the most benefit to an individual patient. Further evaluation of individual patient results through Exscientia’s genomics and transcriptomics capabilities may help Exscientia further understand which other patients may benefit from similar treatments. The underlying technology was developed by Dr. Gregory Vladimer and Prof. Berend Snijder while working in the laboratory of Giulio Superti-Furga at the CeMM Research Center for Molecular Medicine in Austria.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations with respect to the progress of development of candidate molecules, timing and progress of, and data reported from, preclinical studies and clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding its precision medicine platform and AI-driven drug discovery platform. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions, including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors:
Sara Sherman
investors@exscientia.ai

Media:
Amanda Galgay
media@exscientia.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Q4 Inc. Recognized as one of Canada's Top Growing Companies by The Globe and Mail23.9.2022 23:09:00 EEST | Press release

Q4 Inc. (TSX:QFOR), (“Q4” or “the Company”) is pleased to announce their ranking on the 2022 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 Inc. earned its spot with three-year growth of 220%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the third consecutive year by The Globe and Mail,” remarked founder and CEO, Darrell Heaps. “We are extremely proud of the growth we have achieved together as a company and this recognition is a true reflection of the dedication our employees have to helping our clients win in the capital markets.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to celebrate the boldest entrepreneurial achievement by identifying and bringing the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary programs; companies had to complete an in-depth ap

PCT International Hires Dynamic CFO23.9.2022 22:40:00 EEST | Press release

PCT International’s continued resurgence in the broadband and telecommunications market received a boost from the hiring of Simit Shah as Chief Financial Officer. With 20 years of domestic and global treasury, capital markets, and corporate finance experience, Shah is excited to showcase PCT’s strength to the market. Shah will influence the evaluation and structuring of financing strategies, leveraging his experience to drive business transformation from his previous roles. Shah holds a B.S. in Chemistry from Villanova University and an M.B.A from the University of Michigan Ross School of Business. “PCT’s 25-year commitment to innovation, made this an easy choice for me to join their robust team in Tempe,” said Shah. In his previous positions, Shah successfully negotiated, structured, and managed multiple financing facilities and strategies, including being an integral member of the team that transitioned the largest publicly traded proprietary education company to a privately held ent

GCCA: Cement and Concrete Industry Scales Up Carbon Capture, Utilisation and Storage (CCUS) Efforts to Accelerate Decarbonisation23.9.2022 19:30:00 EEST | Press release

The Clean Energy Ministerial CCUS (CEM CCUS) and the Global Cement and Concrete Association (GCCA) have today, at the first-ever Global Clean Energy Action Forum (GCEAF), announced an agreement that will help scale up the deployment of carbon capture, utilisation and storage (CCUS) throughout the cement and concrete industry, in a move to stimulate innovation, investment and increase the pace of decarbonisation efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005359/en/ Major CCUS industry and government collaboration announced at Global Clean Energy Action Forum (GCEAF) in Pittsburgh, USA. Left to right: Thomas Guillot, CEO of the Global Cement and Concrete Association, Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway, Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy (Photo: Bus

Justin Boxford Appointed Global Brand President, Estée Lauder23.9.2022 16:00:00 EEST | Press release

Today, The Estée Lauder Companies (NYSE:EL) announced that Justin Boxford has been appointed Global Brand President, Estée Lauder, effective September 1, 2022. Justin succeeds Stéphane de La Faverie, whose promotion to Executive Group President was part of an organizational evolution announced last week. In his new role, Justin is reporting to Stéphane and will continue to serve on the company’s Executive Leadership Team (ELT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005308/en/ Justin Boxford appointed Global Brand President, Estée Lauder; photo courtesy of Kevin Trageser. As Global Brand President, Justin will be responsible for driving Estée Lauder’s short- and long-term strategy, including innovation, product development, North America and international growth, consumer marketing and distribution evolution. He will partner closely with members of the global Estée Lauder leadership team to drive the brand’s su

XPENG G9 Equipped with Dual Automotive-Grade LiDAR Sensors from RoboSense23.9.2022 15:00:00 EEST | Press release

RoboSense, a world-leading provider of Smart LiDAR Sensor Systems announced XPENG G9 equipped with two RoboSense second-generation Smart Solid-state LiDARs (RS-LiDAR-M1). On September 21, XPENG Motors held the “G9 Flagship SUV Immersive Experience” online launch event and officially launched XPENG G9. XPENG G9 is positioned as “the world’s Fastest-Charging electric SUV”. It achieved a breakthrough and went going from development of “independent functions” to “global intelligence”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005230/en/ XPENG G9 equipped with two RoboSense second-generation smart solid-state LiDARs, to realize full-scenario intelligent driver assistance. (Graphic: Business Wire) G9 further demonstrates XPENG’s innovation in the field of intelligence. From the early functions of autonomous parking, voice control to driver assistance, G9 uses XPENG’s second-generation ADAS, XNGP, equipped with two RoboS

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom